Accelerate Diagnostics In...

NASDAQ: AXDX · Real-Time Price · USD
0.56
0.05 (9.80%)
At close: May 02, 2025, 2:58 PM

Accelerate Diagnostics Statistics

Share Statistics

Accelerate Diagnostics has 25.21M shares outstanding. The number of shares has increased by 14.33% in one year.

Shares Outstanding 25.21M
Shares Change (YoY) 14.33%
Shares Change (QoQ) 0.67%
Owned by Institutions (%) 1.31%
Shares Floating n/a
Failed to Deliver (FTD) Shares 120
FTD / Avg. Volume 0.3%

Short Selling Information

The latest short interest is 292.81K, so 1.17% of the outstanding shares have been sold short.

Short Interest 292.81K
Short % of Shares Out 1.17%
Short % of Float 1.74%
Short Ratio (days to cover) 4.26

Valuation Ratios

The PE ratio is -0.56 and the forward PE ratio is -1.44. Accelerate Diagnostics's PEG ratio is 0.01.

PE Ratio -0.56
Forward PE -1.44
PS Ratio 2.39
Forward PS 0.6
PB Ratio -0.5
P/FCF Ratio -1.13
PEG Ratio 0.01
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Accelerate Diagnostics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 0.71, with a Debt / Equity ratio of -1.19.

Current Ratio 0.71
Quick Ratio 0.62
Debt / Equity -1.19
Debt / EBITDA -1.98
Debt / FCF -2.7
Interest Coverage -2.69

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $109,327.1
Profits Per Employee $-467,710.28
Employee Count 107
Asset Turnover 0.41
Inventory Turnover 3.15

Taxes

Income Tax -66K
Effective Tax Rate 0.13%

Stock Price Statistics

The stock price has increased by -45.85% in the last 52 weeks. The beta is 0.46, so Accelerate Diagnostics's price volatility has been higher than the market average.

Beta 0.46
52-Week Price Change -45.85%
50-Day Moving Average 0.85
200-Day Moving Average 1.35
Relative Strength Index (RSI) 26.72
Average Volume (20 Days) 39,532

Income Statement

In the last 12 months, Accelerate Diagnostics had revenue of 11.7M and earned -50.05M in profits. Earnings per share was -2.15.

Revenue 11.7M
Gross Profit 2.7M
Operating Income -35.31M
Net Income -50.05M
EBITDA -33.57M
EBIT -36.99M
Earnings Per Share (EPS) -2.15
Full Income Statement

Balance Sheet

The company has 15.1M in cash and 66.58M in debt, giving a net cash position of -51.48M.

Cash & Cash Equivalents 15.1M
Total Debt 66.58M
Net Cash -51.48M
Retained Earnings n/a
Total Assets 28.56M
Working Capital -8.96M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -24.19M and capital expenditures 0, giving a free cash flow of -24.7M.

Operating Cash Flow -24.19M
Capital Expenditures n/a
Free Cash Flow -24.7M
FCF Per Share -1.06
Full Cash Flow Statement

Margins

Gross margin is 23.12%, with operating and profit margins of -301.85% and -427.81%.

Gross Margin 23.12%
Operating Margin -301.85%
Pretax Margin -428.37%
Profit Margin -427.81%
EBITDA Margin -287%
EBIT Margin -301.85%
FCF Margin -211.17%

Dividends & Yields

AXDX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for AXDX is $1, which is 96.1% higher than the current price. The consensus rating is "Hold".

Price Target $1
Price Target Difference 96.1%
Analyst Consensus Hold
Analyst Count 1
Stock Forecasts

Stock Splits

The last stock split was on Jul 12, 2023. It was a backward split with a ratio of 1:10.

Last Split Date Jul 12, 2023
Split Type backward
Split Ratio 1:10

Scores

Altman Z-Score -4.14
Piotroski F-Score 2